Michael Burkes Brophy Sells 446 Shares of Natera Inc (NTRA) Stock

Natera Inc (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 446 shares of the stock in a transaction dated Monday, September 24th. The shares were sold at an average price of $23.78, for a total value of $10,605.88. Following the completion of the sale, the chief financial officer now owns 1,117 shares of the company’s stock, valued at $26,562.26. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Michael Burkes Brophy also recently made the following trade(s):

  • On Friday, September 14th, Michael Burkes Brophy sold 108,108 shares of Natera stock. The shares were sold at an average price of $24.31, for a total value of $2,628,105.48.
  • On Monday, July 2nd, Michael Burkes Brophy sold 26,870 shares of Natera stock. The shares were sold at an average price of $18.29, for a total value of $491,452.30.

Shares of NASDAQ:NTRA opened at $24.78 on Thursday. Natera Inc has a 52-week low of $8.60 and a 52-week high of $29.62. The stock has a market capitalization of $1.54 billion, a PE ratio of -10.33 and a beta of 2.21. The company has a debt-to-equity ratio of -3.32, a current ratio of 1.69 and a quick ratio of 1.56.

Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Wednesday, August 8th. The medical research company reported ($0.55) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.55). Natera had a negative return on equity of 752.93% and a negative net margin of 59.07%. The firm had revenue of $63.07 million during the quarter, compared to analysts’ expectations of $61.71 million. During the same period last year, the business posted ($0.55) earnings per share. The company’s revenue for the quarter was up 20.6% compared to the same quarter last year. equities analysts predict that Natera Inc will post -2.05 earnings per share for the current fiscal year.

A number of hedge funds have recently made changes to their positions in NTRA. Sofinnova Ventures Inc purchased a new position in Natera during the first quarter valued at approximately $28,742,000. Fred Alger Management Inc. purchased a new position in Natera during the second quarter valued at approximately $33,271,000. Millennium Management LLC raised its position in Natera by 135.5% during the second quarter. Millennium Management LLC now owns 744,598 shares of the medical research company’s stock valued at $14,013,000 after acquiring an additional 428,376 shares in the last quarter. BlackRock Inc. raised its position in Natera by 19.4% during the second quarter. BlackRock Inc. now owns 2,086,829 shares of the medical research company’s stock valued at $39,274,000 after acquiring an additional 338,766 shares in the last quarter. Finally, Renaissance Technologies LLC raised its position in Natera by 35.2% during the second quarter. Renaissance Technologies LLC now owns 792,400 shares of the medical research company’s stock valued at $14,913,000 after acquiring an additional 206,471 shares in the last quarter. Institutional investors own 66.31% of the company’s stock.

A number of equities research analysts have commented on the company. BidaskClub cut Natera from a “buy” rating to a “hold” rating in a research note on Tuesday, September 11th. Zacks Investment Research upgraded Natera from a “sell” rating to a “hold” rating in a research note on Wednesday, July 11th. Craig Hallum raised their price objective on Natera from $23.00 to $30.00 and gave the stock a “buy” rating in a research note on Thursday, August 9th. Piper Jaffray Companies restated an “overweight” rating and issued a $21.00 price objective (up from $18.00) on shares of Natera in a research note on Thursday, July 5th. Finally, Canaccord Genuity raised their price objective on Natera from $19.00 to $20.00 and gave the stock a “buy” rating in a research note on Monday, June 25th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. Natera currently has a consensus rating of “Buy” and an average target price of $23.14.

Natera Company Profile

Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

See Also: Trading Strategy

Insider Buying and Selling by Quarter for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply